Brief: Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study
Nov 5 (Reuters) - Zai Lab Ltd 9688.HK: UPDATE ON AMGEN'S BEMARITUZUMAB PHASE 1B/3 FORTITUDE-102 STUDY AMGEN STOPS PHASE 1B/3 TRIAL FOR INADEQUATE EFFICACY Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows